

91. Kitahara Y, Saito F, Akao M *et al.* Effect of morning and bedtime dosing with cilnidipine on blood pressure, heart rate, and sympathetic nervous activity in essential hypertensive patients. *J Cardiovasc Pharmacol* 2004; 43:68–73.
92. Wellington K, Scott LJ. Azelnidipine. *Drugs* 2003; 63:2613–2621.
93. Pickering TG, Levenstein M, Walmsley P. Differential effects of doxazosin on clinic and ambulatory pressure according to age, gender, and presence of white coat hypertension. Results of the HALT Study. Hypertension and Lipid Trial Study Group. *Am J Hypertens* 1994; 7:848–852.
94. Pickering TG, Levenstein M, Walmsley P. Nighttime dosing of doxazosin has peak effect on morning ambulatory blood pressure. Results of the HALT Study. Hypertension and Lipid Trial Study Group. *Am J Hypertens* 1994; 7:844–847.
95. Naito Y, Tsujino T, Fujioka Y *et al.* Augmented diurnal variations of the cardiac renin-angiotensin system in hypertensive rats. *Hypertension* 2002; 40:827–833.
96. Kuroda T, Kario K, Hoshida S *et al.* Effects of bedtime vs. morning administration of the long-acting lipophilic angiotensin-converting enzyme inhibitor trandolapril on morning blood pressure in hypertensive patients. *Hypertens Res* 2004; 27:15–20.
97. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. *Lancet* 2000; 355:253–259.
98. Svensson P, de Faire U, Sleight P *et al.* Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. *Hypertension* 2001; 38:E28–E32.
99. Dahlof B, Devereux RB, Kjeldsen SE *et al.*; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet* 2002; 359:995–1003.
100. Lithell H, Hansson L, Skoog I *et al.*; SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. *J Hypertens* 2003; 21:875–886.

101. Pfeffer MA, Swedberg K, Granger CB *et al.*; CHARM Investigators and Committees. **Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.** *Lancet* 2003; **362**:759–766.
102. Julius S, Kjeldsen SE, Weber M *et al.*; VALUE trial group. **Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.** *Lancet* 2004; **363**:2022–2031.
103. Kario K, Pickering TG. **VALUE: analysis of results.** *Lancet* 2004; in press.
104. Bumier M, Brunner HR. **Angiotensin II receptor antagonists.** *Lancet* 2000; **355**:637–645.
105. Eguchi K, Kario K, Shimada K. **Comparison of candesartan with lisinopril on ambulatory blood pressure and morning surge in patients with systemic hypertension.** *Am J Cardiol* 2003; **92**:621–624.
106. White WB, Lacourciere Y, Davidai G. **Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period.** *Am J Hypertens* 2004; **17**:347–353.
107. Smith DHG, Cramer M-JM, Neutel J *et al.* **Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies.** *Blood Press Monit* 2003; **8**:111–117.
108. Lacourciere Y, Gil-Extremera B, Mueller O *et al.* **Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension.** *Int J Clin Pract* 2003; **57**:273–279.
109. Neutel J, Chrysant SG, Littlejohn TW. **Telmisartan 40 or 80mg/HCT 12.5mg fixed dose combinations provide superior BP reductions compared to losartan 50mg/HCT12.5mg fixed dose combination during the last 6 hours of the dosing interval: an ABPM comparison.** 19th Annual Scientific Meeting of the American Society of Hypertension, New York. *Am J Hypertens* 2004.
110. Lacourciere Y, Krzesinski JM, White WB *et al.* **Sustained antihypertensive activity of telmisartan compared with valsartan.** *Blood Press Monit* 2004; **9**:203–210.

-
111. Lacourciere Y, Lenis J, Orchard R *et al.*; on behalf the Canadian Telmisartan Study Group. **A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine.** *Blood Press Monit* 1998; **3**:295–302.
112. Ragot S, Ezzaher A, Meunier A *et al.* **Comparison of trough effect of telmisartan vs perindopril using self blood pressure measurement: EVEREST study.** *J Hum Hypertens* 2002; **16**:865–873.
113. Lacourciere Y, Neutel J, Koval SE *et al.* **A prospective, randomized investigation of the safety and efficacy of telmisartan vs ramipril in mild-to-moderate hypertensives using ambulatory blood pressure monitoring.** 9th Annual Meeting of the European Council for Blood Pressure and Cardiovascular Research (ECCR), Nice. 1–3 October 2004. *Hypertension* 2004; **44**:576.
114. Williams B, Grosse P, Lowe L *et al.* **Superior BP reduction in the last 6 h of the dosing interval with once-daily telmisartan vs ramipril.** 9th Annual Meeting of the European Council for Blood Pressure and Cardiovascular Research (ECCR), Nice. 1–3 October 2004. *Hypertension* 2004; **44**:576.
115. Benson SC, Pershadsingh HA, Ho CI *et al.* **Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR γ -modulating activity.** *Hypertension* 2004; **43**:993–1002.
116. Schupp M, Janke J, Clasen R *et al.* **Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor- γ activity.** *Circulation* 2004; **109**:2054–2057.
117. Rosano GM, Vitale C, Castiglioni A *et al.* **Comparative effects of telmisartan and losartan on glucose metabolism in hypertensive patients with metabolic syndrome.** American Heart Association Scientific Sessions 2004. New Orleans, USA. *Circulation* 2004.
118. Derosa G, Cicero AFG, Bertone G *et al.* **Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study.** *Clin Ther* 2004; **26**:1228–1236.

119. Derosa G, Ragonesi PD, Mugellini A *et al.* Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. *Hypertens Res* 2004; 27:457–464.
120. Weber M. The telmisartan Programme of Research to show Telmisartan End-organ protection potential (PROTECTION) programme. *J Hypertens* 2003; 21 (Suppl 6):S37–S46.
121. Nakagawa H, Morikawa Y, Okayama A *et al.* Trends in blood pressure and urinary sodium and potassium excretion in Japan: reinvestigation in the 8th year after the Intersalt Study. *J Hum Hypertens* 1999; 13:735–741.
122. Teo K, Yusuf S, Anderson C *et al.*; ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE intolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) trials. *Am Heart J* 2004; 148:52–61.
123. The PROFESS Collaborative Group. The largest stroke trial ever to investigate the prevention of recurrent stroke 15,500 patients from up to 600 centers and 26 countries worldwide during 2003–2007. 29th International Stroke Conference, San Diego California, 5–7 February 2004.